Innovent Dosed First Participant in Phase 3 Clinical Study of IBI310 in Combination With Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy

Innovent Biologics, Inc. announced that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase III clinical trial, for resectable mismatch repair deficient colon cancer neoadjuvant therapy.
[Innovent Biologics, Inc.]
Press Release